Form 6K CytoMed Therapeutics Ltd For: 21 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CytoMed Therapeutics Ltd (GDTC)
CytoMed Therapeutics Ltd stock price live, this page displays NASDAQ GDTC stock exchange data. View the GDTC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the CytoMed Therapeutics Ltd real time stock price chart below.
What Is the CytoMed Therapeutics Ltd Stock Price Today?
The CytoMed Therapeutics Ltd stock price today is 1.870.
What Is the Stock Symbol for CytoMed Therapeutics Ltd?
The stock symbol for CytoMed Therapeutics Ltd is ""GDTC.""
What Stock Exchange Does CytoMed Therapeutics Ltd Trade On?
CytoMed Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is CytoMed Therapeutics Ltd a Good Stock to Buy?
Determining whether CytoMed Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GDTC quote. (ISIN: SGXZ17669631)
What Is the CytoMed Therapeutics Ltd Stock Price Today?
The CytoMed Therapeutics Ltd stock price today is 1.870.
What Is the Stock Symbol for CytoMed Therapeutics Ltd?
The stock symbol for CytoMed Therapeutics Ltd is ""GDTC.""
What Stock Exchange Does CytoMed Therapeutics Ltd Trade On?
CytoMed Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is CytoMed Therapeutics Ltd a Good Stock to Buy?
Determining whether CytoMed Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GDTC quote. (ISIN: SGXZ17669631)
NASDAQ
Currency in USD
1.870
+0.010(+0.54%)
Closed·
After Hours
1.8700.000(0.00%)
·
Fair Value
An estimate of a CytoMed Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.850
1.878
52 wk Range
1.200
4.050
GDTC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
GDTC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a CytoMed Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.8501.878
52 wk Range
1.2004.050
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GDTC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a CytoMed Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
CytoMed Therapeutics Ltd Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Compare GDTC to Peers and Sector
Metrics to compare | GDTC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGDTCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.0x | −0.6x | −0.5x | |
PEG Ratio | −0.25 | 0.01 | 0.00 | |
Price/Book | 3.1x | 1.7x | 2.6x | |
Price / LTM Sales | 55.1x | 8.3x | 3.3x | |
Upside (Analyst Target) | 167.4% | 318.4% | 43.5% | |
Fair Value Upside | Unlock | 6.9% | 6.8% | Unlock |
Earnings
Latest Release
May 28, 2025
EPS / Forecast
-- / -0.04
Revenue / Forecast
-- / 130.00K
People Also Watch
FAQ
What Stock Exchange Does CytoMed Therapeutics Trade On?
CytoMed Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for CytoMed Therapeutics?
The stock symbol for CytoMed Therapeutics is "GDTC."
What Is the CytoMed Therapeutics Market Cap?
As of today, CytoMed Therapeutics market cap is 21.58M.
What Is CytoMed Therapeutics's Earnings Per Share (TTM)?
The CytoMed Therapeutics EPS (TTM) is -0.22.
When Is the Next CytoMed Therapeutics Earnings Date?
CytoMed Therapeutics will release its next earnings report on 13 Nov 2025.
From a Technical Analysis Perspective, Is GDTC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has CytoMed Therapeutics Stock Split?
CytoMed Therapeutics has split 0 times.
How Many Employees Does CytoMed Therapeutics Have?
CytoMed Therapeutics has 43 employees.
What is the current trading status of CytoMed Therapeutics (GDTC)?
As of 09 Aug 2025, CytoMed Therapeutics (GDTC) is trading at a price of 1.87, with a previous close of 1.86. The stock has fluctuated within a day range of 1.85 to 1.88, while its 52-week range spans from 1.20 to 4.05.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.